Back to User profile » Professor Hikmat Abdel-Razeq

Papers published by Professor Hikmat Abdel-Razeq:

Aggressiveness of Cancer Care at End of Life in Patients with Metastatic Breast Cancer in Jordan

Abunasser M, Abu-Fares H, Abdel-Razeq S, Shamieh O, Salama O, Ashouri K, Al Qudah A, Taqash A, Abu-Jaish H, Saadah SS, Abdel-Razeq H

Journal of Multidisciplinary Healthcare 2023, 16:2873-2881

Published Date: 26 September 2023

Differences in Treatment Outcomes Between Patients with HER2-Low versus HER2-Zero, Hormone Receptor-Positive Advanced-Stage Breast Cancer Treated with Ribociclib

Sharaf B, Abu-Fares H, Tamimi F, Al-Sawajneh S, Salama O, Daoud R, Alhajahjeh A, Al-Lababidi S, Abdel-Razeq H

Breast Cancer: Targets and Therapy 2023, 15:541-548

Published Date: 28 July 2023

Guideline-Based, Multi-Gene Panel Germline Genetic Testing for at-Risk Patients with Breast Cancer

Abdel-Razeq H, Abujamous L, Al-Azzam K, Abu-Fares H, Bani Hani H, Alkyam M, Sharaf B, Elemian S, Tamimi F, Abuhijla F, Edaily S, Salama O, Abdulelah H, Daoud R, Abubaker M, Al-Atary A

Breast Cancer: Targets and Therapy 2023, 15:1-10

Published Date: 13 January 2023

Clinical Characteristics and Survival Outcomes of Patients with De Novo Metastatic Breast Cancer

Almasri H, Erjan A, Abudawaba H, Ashouri K, Mheid S, Alnsour A, Abdel-Razeq H

Breast Cancer: Targets and Therapy 2022, 14:363-373

Published Date: 29 October 2022

Breast Cancer in Geriatric Patients: Current Landscape and Future Prospects

Abdel-Razeq H, Abu Rous F, Abuhijla F, Abdel-Razeq N, Edaily S

Clinical Interventions in Aging 2022, 17:1445-1460

Published Date: 28 September 2022

Clinical Characteristics, Prognostic Factors and Treatment Outcomes of Patients with Bone-Only Metastatic Breast Cancer

Marie L, Braik D, Abdel-Razeq N, Abu-Fares H, Al-Thunaibat A, Abdel-Razeq H

Cancer Management and Research 2022, 14:2519-2531

Published Date: 23 August 2022

Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data

Abdel-Razeq H, Sharaf B, AlMasri R, Abdel-Razeq R, Tamimi F, Khader O, Salama O, Abunasser M, Edaily S, Abdulelah H

Cancer Management and Research 2022, 14:1033-1041

Published Date: 8 March 2022

Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives

Abdel-Razeq H, Tamimi F, Abujamous L, Edaily S, Abunasser M, Bater R, Salama O

Cancer Management and Research 2021, 13:4597-4604

Published Date: 9 June 2021

Clinicopathological Characteristics And Treatment Outcomes Of Breast Cancer Among Adolescents And Young Adults In A Developing Country

Abdel-Razeq H, Almasri H, Abdel Rahman F, Abdulelah H, Abu Nasser M, Salam M, Al-Dairi A, Natour O, Rimawi D

Cancer Management and Research 2019, 11:9891-9897

Published Date: 22 November 2019

Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients

Abdel-Razeq H, Saadeh SS, Abu-Nasser M, Abdulelah H, Marie L, Salam M, Al-Haj Ali B, Ibrahim M, Rimawi D

OncoTargets and Therapy 2018, 11:2091-2096

Published Date: 11 April 2018

The application of clinical variables and models to predict pulmonary embolism in cancer patients: a comprehensive single cancer center experience

Mansour A, Ismael Y, Abunasser M, Hammode E, Turfa R, Abdel-Razeq H

Patient Preference and Adherence 2013, 7:1111-1116

Published Date: 23 October 2013

Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study

Abdel-Razeq H, Abbasi S, Saadi I, Jaber R , Abdulelah H

Drug Design, Development and Therapy 2013, 7:939-944

Published Date: 30 August 2013

Current neoadjuvant treatment options for HER2 positive breast cancer

Abdel-Razeq H, Marei L

Biologics: Targets and Therapy 2011, 5:87-94

Published Date: 9 August 2011

Incidental pulmonary embolism in cancer patients: clinical characteristics and outcome – a comprehensive cancer center experience

Hikmat N Abdel-Razeq, Asem H Mansour, Yousef M Ismael

Vascular Health and Risk Management 2011, 7:153-158

Published Date: 15 March 2011

Inferior vena cava filters in cancer patients: to filter or not to filter

Hikmat Abdel-Razeq, Asem Mansour, Yousef Ismael, et al

Therapeutics and Clinical Risk Management 2011, 7:99-102

Published Date: 10 March 2011